Aveo, Novartis scrap $326m antibody licensing deal

This article was originally published here

US-based Aveo Pharmaceuticals and Swiss drugmaker Novartis have scrapped their $326m worth licensing agreement to develop and commercialize the former’s humanized inhibitory antibody AV-380 and other related antibodies.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply